Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives $26.50 Average PT from Analysts

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPNGet Free Report) have earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $26.50.

Several analysts have weighed in on ALPN shares. HC Wainwright boosted their price target on Alpine Immune Sciences from $17.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Morgan Stanley raised their target price on Alpine Immune Sciences from $17.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, November 3rd. Berenberg Bank began coverage on Alpine Immune Sciences in a report on Tuesday, October 17th. They set a “buy” rating and a $18.00 target price on the stock. Royal Bank of Canada raised their target price on Alpine Immune Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Finally, Wedbush raised their target price on Alpine Immune Sciences from $26.00 to $35.00 and gave the stock an “outperform” rating in a report on Friday, January 26th.

Read Our Latest Stock Report on Alpine Immune Sciences

Insider Buying and Selling at Alpine Immune Sciences

In other news, insider James Paul Rickey sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $19.00, for a total value of $34,200.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider James Paul Rickey sold 1,800 shares of Alpine Immune Sciences stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $19.00, for a total transaction of $34,200.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Mitchell Gold sold 8,067 shares of Alpine Immune Sciences stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $17.08, for a total value of $137,784.36. Following the transaction, the chief executive officer now owns 101,320 shares in the company, valued at approximately $1,730,545.60. The disclosure for this sale can be found here. Over the last three months, insiders have sold 315,182 shares of company stock valued at $6,162,851. Company insiders own 42.30% of the company’s stock.

Institutional Investors Weigh In On Alpine Immune Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Decheng Capital LLC acquired a new position in Alpine Immune Sciences during the 4th quarter worth $135,007,000. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Alpine Immune Sciences in the 3rd quarter valued at about $76,810,000. BlackRock Inc. increased its position in Alpine Immune Sciences by 46.9% in the 2nd quarter. BlackRock Inc. now owns 2,281,692 shares of the biotechnology company’s stock valued at $23,456,000 after acquiring an additional 728,772 shares during the period. Vanguard Group Inc. increased its position in Alpine Immune Sciences by 5.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,474,879 shares of the biotechnology company’s stock valued at $16,887,000 after acquiring an additional 70,912 shares during the period. Finally, Franklin Resources Inc. acquired a new position in Alpine Immune Sciences during the 4th quarter worth approximately $23,260,000. Institutional investors and hedge funds own 75.17% of the company’s stock.

Alpine Immune Sciences Price Performance

Shares of ALPN stock opened at $30.38 on Tuesday. Alpine Immune Sciences has a 1-year low of $6.39 and a 1-year high of $30.65. The stock’s fifty day moving average price is $21.01 and its 200 day moving average price is $15.45. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -25.32 and a beta of 1.07.

Alpine Immune Sciences (NASDAQ:ALPNGet Free Report) last announced its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.11. Alpine Immune Sciences had a negative return on equity of 33.53% and a negative net margin of 185.10%. The firm had revenue of $10.04 million for the quarter, compared to the consensus estimate of $8.73 million. As a group, equities research analysts anticipate that Alpine Immune Sciences will post -1.14 earnings per share for the current year.

Alpine Immune Sciences Company Profile

(Get Free Report

Alpine Immune Sciences, Inc operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development.

Further Reading

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.